Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

4D Pharma posts "exciting" development results from MicroRx

Tue, 16th Jun 2015 08:33
Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx.The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis.The group also identified bacteria that have "therapeutically relevant" effects in an industry standard model of multiple sclerosis.Furthermore, its pre-clinical work showed "clear efficacy" in preventing the development of multiple sclerosis.Chief scientific officer Alex Stevenson said: "These results are an exciting development in the progress of live biotherapeutics."To potentially treat a disease such as multiple sclerosis with an oral capsule of therapeutically functional bacteria would be a huge step forward in the treatment of this disease."Shares were up 3.76% to 897.5p on Tuesday at 08:32.

Related News

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM
15 Feb 2023

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June ...

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil
3 Feb 2023

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

DDDD.L News

IN BRIEF: 4D Pharma shares to be delisted from Nasdaq
28 Jun 2022

IN BRIEF: 4D Pharma shares to be delisted from Nasdaq

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says it has received written notice from the Nasdaq Stock Market that its securities wil...

IN BRIEF: 4d Pharma faces uncertain future as loan repayment due
24 Jun 2022

IN BRIEF: 4d Pharma faces uncertain future as loan repayment due

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has "no immediate certainty" of how it will repay the USD13.9 million loan facil...

IN BRIEF: 4d Pharma suspends trading immediately, pending announcement
24 Jun 2022

IN BRIEF: 4d Pharma suspends trading immediately, pending announcement

4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has ordered an immediate suspension of trading in the company's shares on AIM pe...

4D Pharma requests immediate suspension of its shares
24 Jun 2022

4D Pharma requests immediate suspension of its shares

(Sharecast News) - Biotherapeutics developer 4D Pharma requested an immediate suspension of trading in its shares on Friday.

4D Pharma reports progress in bladder cancer trial
27 May 2022

4D Pharma reports progress in bladder cancer trial

(Sharecast News) - Live biotherapeutics developer 4D Pharma announced progress in the phase 2 clinical trial in bladder cancer on Friday.

IN BRIEF: 4D Pharma plans to test MRx0518 in combination with Bavencio
27 May 2022

IN BRIEF: 4D Pharma plans to test MRx0518 in combination with Bavencio

4D Pharma PLC - Leeds, England-based pharmaceutical company - Plans to conduct a phase II study to assess the safety of MRx0518 in combination with Ba...

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial
17 May 2022

IN BRIEF: 4D Pharma rises as asthma drug moves on to part B of trial

4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed th...